



***IN VITRO* ANTIOXIDANT IMPACT OF ASCORBIC ACID ON CONJUGATED  
DIENE AND MALONDIALDEHYDE FORMATION IN COPPER MEDIATED  
OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN, ISOLATED  
FROM NOVICE SMOKER PLASMA**

Deepti Malhotra<sup>3</sup>, Fouzia Ishaq<sup>2</sup>, Amir Khan\*<sup>1</sup>

<sup>1</sup>Department of Biochemistry, Division of Life Science, Sardar Bhagwan Singh Post Graduate Institute of Biomedical Sciences & Research Balawala, 248161, Dehradun, UK, India.

<sup>2</sup>Department of Env. Science and Zoology, Gurukul Kangri University, Haridwar, Uttarakhand

<sup>3</sup>Dept. of Biotechnology, Shri Guru Ram Rai (P.G) College, Dehradun, U.K, India

### ABSTRACT

Cigarette smoking contains a large number of oxidants leading to the production of free radicals which results for oxidative damage to critical biologic substance. Tobacco epidemic death toll is 100 million in the 20th century which is estimated to be one billion during the 21st century. Currently 5.4 million deaths every year but by 2030 it may rise to 8 million deaths every year Cigarette smoking is a mixture of over 4000 chemicals containing bioactive substances. One puff of a cigarette exposes the smoker to more than 1015 free radicals and other oxidants and additional free radicals and oxidants are found in the tar of a cigarette. In this study we investigated the efficacy of antioxidant agent Vit. C by analyzing all the parameters in plasma, VLDL-C, LDL-C, HDL-C, HDL2-C, HDL3-C, LDL-P, HDL-P, VLDL-P, TBAR, MDA and *invitro* oxidizability of LDL in absence and presence of Vit. C. In this study, ex-viva Baseline Diene Conjugation level and Malondialdehyde values of young smokers to significantly increase in comparison to normal control values. After the Cu<sup>2+</sup> mediated oxidation of LDL were seen to increase. *Invitro* LDL oxidation was carried out in the presence of Vit. C, which decreased the maximum amount of CD of LDL oxidation after 4 hrs incubation. These results indicate that Vit. C has strong anti-oxidative properties. On the other hand, Our result showed a significant decrease value in total antioxidant status in plasma of young smokers and significant increase after treatment with Vitamin C. Ascorbic acid mediated multiple therapeutic benefits in the present study. Daily intake of Vit. C as dietary supplement by young/old/moderate or heavy smokers including passive smokers maybe useful in prevention and treatment of tobacco including hyperlipidemia and atherosclerosis. In addition, daily intake of Vit. C will be efficacious and cost effective.

**Keywords:** Ascorbic acid, atherosclerosis, hyperlipidemia, LDL oxidation, Malondialdehyde and free radicals.

### INTRODUCTION

Smoking has been strongly implicated as a risk factor for chronic obstructive pulmonary disease, cancer and atherosclerosis <sup>[1]</sup>. Cigarette smoking contains a large number of

oxidants leading to the production of free radicals which results for oxidative damage to critical biologic substance <sup>[2]</sup>. Tobacco epidemic death toll is 100 million in the 20th century which is estimated to be one billion during the 21st century <sup>[3]</sup>. Currently 5.4 million deaths every year but by 2030 it may rise to 8 million deaths every year Cigarette smoking is a mixture of over 4000 chemicals containing bioactive substances <sup>[4]</sup>. One puff of a cigarette exposes the smoker to more than 1015 free radicals and other oxidants and additional free radicals and oxidants are found in the tar of a cigarette <sup>[5]</sup>. Further damage may be caused by the endogenous formation of oxidants which affect the inflammatory immune response <sup>[6]</sup>. The burning of tobacco at temperature of 830-900° C leads to the production of about 5000 already identified toxic substances of heterogeneous mixture containing gaseous phase like CO, Nitrogen Oxides, Nitrosamine etc and solid phase which are products of pyrolysis like nicotine, phenols, aromatic polycyclic hydrocarbons in addition to free radicals <sup>[7]</sup>. The solid phase contains relatively stable free radicals while gaseous one contains small free radicals of oxygen, carbon and sulphur, high concentration of nitric acid and aldehyde moieties. The smoke is able to cause tissue oxidative damage at various levels <sup>[8]</sup> and contributes significantly to the appearance of endothelial dysfunction and to the alterations which induce arteriosclerosis <sup>[9]</sup>. Increase in lipid per oxidation products <sup>[10]</sup> particularly important for increase in LDL oxidation <sup>[11]</sup> accompanied by a decrease in HDL cholesterol level is reported <sup>[12]</sup>. Tobacco is associated in the active smoker with the occurrence of ischemic cardiopathy, acute myocardial infraction <sup>[13]</sup>, sudden coronary death, arterial hypertension <sup>[14]</sup>, atherosclerosis <sup>[15]</sup> and in passive smoker with increased prevalence of CVD <sup>[16]</sup>. Now a day's Hand smoking is a highly addictive habit involving pharmacological addictions to nicotine. 20% of overall deaths in the industrialized world die from diseases directly linked to smoking <sup>[17]</sup>. The biological effects of smoking include decrease in the level of ascorbic acid in serum <sup>[18]</sup>. Active smokers have more than 25% lower circulating concentration of ascorbic acid, and carotene and cryptoxanthin. Nicotine is absorbed very rapidly and enters circulation stimulates directly the sympathetic nervous system, increasing the secretion of catecholamines produces vasoconstriction reduced oxygen tension, increased arterial blood pressure, contractability of myocardium and cardiac output <sup>[19]</sup>. The evidence supporting the hypothesis that LDL is the major atherogenic

lipoprotein comes from epidemiological studies, clinical trials, studies in lab animals, heritable hypercholesterolemia, pathological investigation, LDL oxidation takes place when naturally occurring antioxidant agents such as Vit. E, carotenes, Vit. C that normally inhibits LDL oxidation does not occur<sup>[20]</sup>. OxLDL consists of a heterogeneous mixture of modified lipid and protein molecules. 'Ascorbic' name comes from the property of Vit. C of preventing and curing scurvy. Primates including humans have lost the ability to synthesize Ascorbic acid and must obtain it in their food. These are water soluble vitamins. The effectiveness of Vit. C in LDL oxidation inhibition is evident from *in vitro* studies<sup>[21]</sup>. Ascorbate prevents oxidative modification of LDL primarily by scavenging free radicals and other reactive species, thereby preventing them from interacting with LDL<sup>[22]</sup> and also by decreased binding of Cu<sup>2+</sup> to LDL due to dehydro- L- ascorbic acid and other decomposition products of ascorbate that react with specific amino acid residues on ApoB, which normally bind Cu<sup>2+</sup> thus decreasing the affinity of these amino acid residues for the metal ion. Ascorbate can also prevent the pro-oxidation activity of  $\alpha$ -tocopherol by reducing the tocopheroxyl radical to tocopherol, thereby acting as a co-antioxidant and inhibiting LDL oxidation<sup>[23]</sup> improved lag phase as observed when Vit. C as supplemented in patients with established CVD combined with Vit. E and carotene<sup>[24]</sup>. Vit. C is able to scavenge both Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). The physiological role of Vit. C stems from its very strong reducing power (high reductive potential) and its ability to be regenerated using intracellular reductants such as Glutathione, nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate. In this study we investigated the efficacy of antioxidant agent Vit. C by analyzing all the parameters in plasma, VLDL-C, LDL-C, HDL-C, HDL2-C, HDL3-C, LDL-P, HDL-P, VLDL-P, TBAR, MDA and *in vitro* oxidizability of LDL in absence and presence of Vit. C.

## MATERIAL AND METHODS

**Chemicals:** All the chemicals used in the study were of analytical grade and procured from standard suppliers like Himedia, Sigma Lab. Pvt. Etc. All the Glasswares used were of Borosil Company and plastic wares from MS Tarson and Himedia. Micropipette from Eppendorf Company, India. Instruments used during study were Electronic balance, pH

meter, centrifuge, spectrophotometer, incubatory rotatory shaker, soxhlet apparatus, autoclave, deep freezer, refrigerator, magnetic stirrer, hot air oven, water bath etc.

**Estimation:** Determination of Nicotine <sup>[25]</sup>, Carbon mono-oxide saturation <sup>[25]</sup>, Plasma Triglycerides <sup>[26]</sup>, Fractionation of plasma lipoproteins such as LDL <sup>[27]</sup>, HDL and its subfractions HDL2 and HDL3 <sup>[28]</sup>, Protein estimation <sup>[29]</sup>, Plasma FRAP <sup>[30]</sup>, LDL oxidation in presence and absence of Vit. C <sup>[31, 32]</sup>, Lipid peroxidation <sup>[33]</sup>, ThioBarbituric Acid reactive substances (TBARS) in LDL <sup>[34]</sup>, ApoB Protein <sup>[29]</sup>, Total Anti Oxidant Power (TAP) <sup>[30]</sup>, Haemoglobin content <sup>[35]</sup>, TBARS in RBC <sup>[36]</sup>. Statistical analysis of data was done by employing two-tailed Student t- test as described by <sup>[37]</sup>. P value less than 0.02 were considered significant.

**Experimental Design:** The research was carried out at the Department of Biotechnology and Pharmaceutical Chemistry, Uttaranchal College of Science and Technology, Dehradun. Healthy young male smoker and non smoker (control) were recruited from the college. All the subjects were ethnically homogenous with similar nutritional habits, free from alcohol consumption and were drinking maximum 3-2 cups of tea a day, had no vitamin intake 3 months before the initiation of the study.

**Collection of Blood and Plasma:** At the end of the experiment treatment, overnight fasted rats in each group were anaesthetized and blood drawn from cardiac puncture. The blood from each rat in a given group was collected in heparinized tubes, mixed gently by inversion 2-3 times and incubated at 4° C for 2-3 hrs. Plasma was separated from the blood by centrifugation at 25000 rpm for 30 min, aliquoted and either stored at 4° C or frozen at -20° C for use in other experiments.

## RESULT & DISCUSSION


**Measurement of Physiological parameter of Non-smokers and Young smokers:** The results for the physiological parameters of age, height, weight, Number of cigarettes/day, Smoking history, Smoking index are shown in Table 1, do not have any significant difference. This depicts that they do not have any significant role in deciphering the smokers from the normal healthy persons.

**TABLE 1: MEASUREMENT OF PHYSIOLOGICAL PARAMETER OF NON-SMOKERS AND YOUNG SMOKERS.**

Parameters	Non-smokers	Young-Smokers
Number	9	11
Male	5	11
Female	4	-
Age (yrs)	20.77±0.186*	23±0.27*
Weight (kg)	54.55±0.15*	65.55±0.15*
Height (cm)	167.66±0.19*	169.63±0.17*
Number of cigarettes/day	-	8±0.301*
Smoking history (yrs)	-	5±0.30*
Smoking Index**	-	22±0.213*

\*Values are mean ± S.D. from all groups of subject \*\*Number of cigarettes per day ×smoking history

**Measurement of Nicotine, Sco%, TC and Lipid Parameters:** The results depicted in Fig. 1 indicate that increase in the levels of Nicotine and Carbon mono-oxide saturation occurred due to smoking of cigarette which also increases the risk of myocardial infraction in young population. Similarly TG, TC, VLDL-C, HDL-C, HDL2-C, HDL3-C, non HDL-C were significantly increased from the normal control value. The results are in accordance to the publications of National Institute of Drug Abuse Reports (2010) and Science Daily. Increased concentration of HDL-C and its subfractions has also been reported by <sup>[38]</sup>. Increase concentration of LDL-C has been proven by <sup>[39]</sup>.




**Figure 1**

Average value of nicotine, Sco%, TC and Lipid Parameters, TC (Total Cholesterol), VLDL-C (Very Low Density Lipoprotein, LDL (Low Density Lipoprotein), Non-HDL value= TC-HDL-C

**Estimation of protein of LDL, HDL & VLDL of non-smokers and young-smokers:**

The results depicted in Fig. 2 indicate that increase in the levels of VLDL-Protein, LDL-Protein but decrease in HDL-Protein for smokers in comparison to non smokers. Similar results were obtained through the work done<sup>[39]</sup> and <sup>[40]</sup>.



**Figure 2**

Estimation of protein of LDL, HDL & VLDL of non-smokers and young-smokers.

**Measurement of the ratios of LDL-C/HDL-C, TC/LDL-C, HDL2-C/HDL3-C & TC/HDL-C:** The results depicted in Table 2 showed significant increase in the ratio of LDL-C/HDL-C and HDL2-C/HDL3-C while decrease in the ratios of TC/LDL-C and TC/HDL-C for young smokers compared to non smokers.

**TABLE 2: MEASUREMENT OF THE RATIO OF LDL-C/HDL-C, TC/LDL-C, HDL2-C/HDL3-C AND TC/HDL-C.**

Parameters	Non-smokers	Young-Smokers
LDL-C/HDL-C	2.685±0.093*	2.755±0.005* (+2.6%)
TC/LDL-C	1.565±0.010*	1.466±0.013* (-1.3%)
HDL2-C/HDL3-C	0.505±0.004*	0.556±0.011* (+10.09%)
TC/HDL-C	4.186±0.005*	3.872±0.006* (-7.50%)

\*Values are mean±S.D. from all groups of subject

**Measurement of Total Antioxidant Power (TAP) in Ascorbic Acid at different concentration:** The results depicted in Table 3 showed the antioxidant impact of Vitamin C. at different concentrations which significantly increased compared to basal value of 10µl/µg. Similar increase in TAP for increasing concentrations of Vit. C was reported by [41] and [42].

**TABLE 3: MEASUREMENT OF TOTAL ANTIOXIDANT POWER (TAP) IN ASCORBIC ACID AT DIFFERENT CONCENTRATION**

Conc (µl/µg)	O.D. at 595nm	TAP (nm/mg)
10	0.307	0.8614 (basal level)
20	0.409	0.9035 (+4.88%)
40	0.6512	1.032 (+19.80)
60	0.752	1.110 (+29.09%)
80	0.883	1.110 (+28.85%)
100	1.186	1.115 (+29.4%)

**Measurement of Total Antioxidant Power (TAP) in lipid parameters:** results depicted in Table 4 showed the antioxidant impact in LDL-C, HDL-C and HDL3-C levels

increased in young smokers compared to non smokers while values of HDL2-C, VLDL-C were decreased from normal control value.

**TABLE 4: AVERAGE VALUE OF TOTAL ANTIOXIDANT POWER IN LIPID PARAMETERS**

Lipoprotein	Non-smoker TAP (nm/mg)	Young-smoker TAP (nm/mg)
VLDL-C	1.025±0.009*	0.212±0.004* (-79.31%)
LDL-C	0.2219±0.0005*	0.655±0.001* (+195.17%)
HDL-C	1.4092±0.0002*	1.873±0.0008* (+32.92%)
HDL2-C	0.8865±0.001*	0.628±0.011* (-29.15%)
HDL3-C	0.535±0.009*	0.639±0.010* (+19.43%)

\*Values are mean±S.D. from all groups of subject

***In vitro* impact of Ascorbic Acid on Total Antioxidant Power (TAP) in Plasma:** results depicted in Table 5 showed for *In vitro* impact of Vit. C on TAP in Plasma isolated from young smokers reduced from non smokers value due to excessive increase in free radicals in smokers which reduces the Ferric Reducing Ability of Plasma (FRAP). *In vitro* treatment of normal and smokers with Vit. C significantly increases with TAP of each group. Oxidative stress may be increased in smokers due to a higher production of Reactive Oxygen Species (ROS) such as hydrogen peroxide, superoxide radical, hydroxyl radical and /or deficiency in in the antioxidant defense system. Therefore as the balance between the ROS production and antioxidant defense loosens, the resultant oxidative stress through a series of events deregulates the cellular functions leading to various pathological damages. Our result showed a significant decrease value in total antioxidant status in plasma of young smokers and significant increase after treatment with Vitamin C results are similar to that predicted by <sup>[43]</sup>.



**TABLE 5: *IN VITRO* IMPACT OF ASCORBIC ACID ON TOTAL ANTIOXIDANT POWER (TAP) IN PLASMA.**

Conc (µl)	Non-smoker TAP (nm/mg)		Young-smoker TAP (nm/mg)	
	ithout Vit. C	ith Vit. C	ithout Vit. C	ith Vit. C
10	0.8405±0.0004*	1.0028±0.001* (+19.30%)	0.8243±0.001*	0.9215±0.004* (+11.79%)
20	0.676±0.014*	0.699±0.017* (+3.4%)	0.865±0.012*	0.9237±0.0007* (+6.78%)

\*Values are mean±S.D. from all groups of subject


***In vitro* antioxidant impact on Conjugated diene and Malondialdehyde formation in LDL Oxidation:** : results depicted in Table 6 shows the ex-viva Baseline Diene Conjugation level and Malondialdehyde values of young smokers to significantly increase in comparison to normal control values. After the Cu<sup>2+</sup> mediated oxidation of LDL were seen to increase. *In vitro* LDL oxidation was carried out in the presence of Vit. C, which decreased the maximum amount of CD of LDL oxidation after 4 hrs incubation. These results indicate that Vit. C has strong anti-oxidative properties.

**TABLE 6: *IN VITRO* ANTIOXIDANT IMPACT ON CONJUGATED DIENE AND MALONDIALDEHYDE FORMATION IN LDL OXIDATION.**


Conc (µl)	Incubation at 37° C	CD formation (nmol/mg Protein)		MDA formation (nmol/mg Protein)	
		Non-smoker	Young - smoker	Non-smoker	Young -smoker
10	0 time	180.25±0.04*	246.19±0.05* (+36.58%)	0.365±0.16*	0.3915±0.001* (+7.26%)
10	0+CuSO <sub>4</sub> (4hrs)	270.32±0.07* (+49.47%)	311.26±0.07* (+26.43%)	0.8004±0.008* (+119.28%)	0.9423±0.0006* (140.68%)
10	CuSO <sub>4</sub> +Vit. C (4 hrs)	210.09±0.02* (-22.28%)	270.45±0.09* (-13.11%)	0.1436±0.001* (-82.05%)	0.4326±0.0008* (-54.03%)

Values are obtained from LDL, isolated from pooled plasma in each group. LDL oxidation (10 µl) as carried out in the absence and presence of Vit. C (10 µl).

\*Value is mean±S.D. from all groups of subject

**Figure 3**

*In vitro* antioxidant impact of vit. C on Conjugated diene after LDL Oxidation

**Figure 4**

*In vitro* antioxidant impact of vit. C on MDA formation after LDL Oxidation

## CONCLUSION

Ascorbic acid mediated multiple therapeutic benefits in the present study. Daily intake of Vit. C as dietary supplement by young/old/moderate or heavy smokers including passive smokers maybe useful in prevention and treatment of tobacco including hyperlipidemia

and atherosclerosis. In addition, daily intake of Vit. C will be efficacious and cost effective.

#### REFERENCES:

1. US Department of Health and Human Services (2001). Women and smoking: a report of Surgeon General Washington DC: *US Govt. Printing Office*.
2. Church, D., Pryor, W.A. (1985). Free Radical Chemistry of cigarette smoke and its toxicological implications. *Env. Health Persp.*; 64: 111-126.
3. World Population Prospects, 2004.
4. Cross, C.E., Traber, M., Eiserich, J. (1999). Micronutrients antioxidants and smoking. *Br Med. Bull.*; 55: 691-704.
5. Pryor, W.A., Prier, D.G., Church, D.F. (1983). Electron spin resonance study of mainstream and sidestream cigarette smoke mature of the free radicals in gas phase smoke and on cigarette tar. *Env. Health Persp.*; 47: 345-355.
6. Alberg, A. (2002). The influence of cigarette smoking on circulating concentration of antioxidant micronutrients. *Toxicology*; 180: 121-137.
7. Pryor, W.A., Stroke, K.(1983). Oxidative damage in tissues of rats exposed to cigarette smoke. *Atherosclerosis*; 168: 169-179.
8. Park, E.M., Park, Y.M., Gwark, Y.S. (1998). Oxidative damage to tissues of rats exposed to cigarette smoking. *Atherosclerosis*; 168: 169-179.
9. Lakier, J.B.(1992). Smoking and CVD. *Am. J. Med*; 93: 10-15.
10. Smith, F.B., Lowe, G.D.O. (1993). Smoking, haemostatic factors and lipid peroxidation in a population case control study of peripheral arterial disease. *Atherosclerosis*; 102: 155-162.
11. Sanderson, K.J., Van, R.A.M., Wade, C.R. (1995). Lipid peroxidation of circulating LDL with age smoking and in peripheral vascular disease. *Atherosclerosis*; 118: 45-51.
12. Schuitmaker, G.E., Dinant, A. (2002). Relationship between smoking and low-density lipoprotein-cholesterol, HDL-Cholesterol and TG in a hypercholesterolemic adult cohort in relation to gender and age. *Clin. Exp. Med.*; 2: 83-88.
13. Morb Mortal Weekly Report (MMWR)(1991). World No-Tobacco Day;40:341-342.

14. Sowers J.R., Epstein M., Frohlich E.D.( 2001 ). Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension.*;37(4):1053-9.
15. Rae-Ellen W., Kavey, Stephen R., Daniels, Ronald M. Lauer, Dianne L. Atkins, Laura L. Hayman, RN; Kathryn Taubert (2003). American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. *Circulation*;107;1562-1566.
16. Glantz S.A., Parmley W.W.(1991). Passive smoking and heart disease: Epidemiology, physiology, and biochemistry. *Circulation*;83:1-12.
17. Peto, R., Doll, R., Sutherland, I. (1992). Mortality in relation to smoking: 50 years observation on male British doctors. *Br. Med. J.*; 328: 1519-28.
18. Schectman G., Kaul S., Kissebah A.H.( 1989). Heterogeneity of low density lipoprotein responses to fish-oil supplementation in hypertriglyceridemic subjects. *Arterioscler Thromb Vasc Biol.*;9;345-354.
19. World Health Organization (2002). Smoking statistics. URL [http://www.wpro.who.int/media\\_centre/fact\\_sheets/fs\\_20020528.htm](http://www.wpro.who.int/media_centre/fact_sheets/fs_20020528.htm).
20. Washington, D.C.( 1990). The Health Benefits of Smoking Cessation. A report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. *DHHS (CDC)*;90-8416.
21. Martin, A., Frie, B. (1999). Both intracellular and extracellular Vitamin C inhibit atherogenic modification of LDL bu human vascular endothelium cells. *Atheroscler Thromb. Vas. Bio.*; 14: 1583-90.
22. Retsky, K.L., Freeman, M.W. (1993). Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification: anti-rather than pro-oxidant activity of Vit. C in the presence of transition metal ions. *J. Bio. Chem.*; 268: 1304-9.
23. Harats, D., Chevion, S., Nahir, M. (1998). Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between Vit. C and E in vivo. *Ann. J. Clin. Med.*; 67: 240-5.
24. Mc Kechnie, R., Rubenfire, M., Mosca, L. (2002). Antioxidant nutrient

- supplementation and brachid reactivity in patients with coronary artery diseases. *J. Lab. Chin. Med.*; 139: 133-39.
25. Varley H, Gowenlock AH, Bell M.( 1976). Determination of plasma fibrinogen by tyrosin method (Lampert). In “Practical Clinical Biochemistry”, *Heinemann Medical Books, London*, Vol. I; 5TH edition, Chapter 19, 557-8.
  26. Trinder P. (1969). Determination of blood glucose using an oxidase-peroxidase system with a noncarcinogenic chromogen. *J Clin Pathol* ; 22: 485-520.
  27. Wieland, H. and Seidel, D. (1989). A simple method for precipitation of low-density lipoproteins. *Journal of Lipid Research*. 24: 904-909.
  28. Patsch, W, Brown, S. A., Morrisett, J. D., Gotto, Jr., A. M. and Patsch, J. R. (1989). A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. *Clin. Chem*. 35: 265-270.
  29. Bradford, M.M. (1976). A rapid and sensitive method for the quantification protein dye binding of microgram quantities of protein. *Anal. Biochem.*, 72:248-254.
  30. Benzie, I. F. F. and Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. *Analytical Biochem*. 239: 70-76.
  31. Esterbauer, H., Striegel, G., Puhl, H., Oberreither, S., Rotheneder, M., El Saadani, M. and Jurgens, G. (1989). The role of vitamin E and carotenoids in preventing oxidation of low-density lipoproteins. *Ann. N. Y. Acad. Sci*. 570: 254-267.
  32. Esterbauer, H., Puhl, H. (1992). The role of lipid per oxidation and antioxidants in the oxidative modification of LDL. *Free Radical Res. Com*. 13: 341-90.
  33. Nouraz-Zadeh et al., 1996.
  34. Niehaus and Sameulson, 1968.
  35. Van Kampen E., Zijlstra W.G.( 1961). Standardization of hemoglobinometry. II. The hemiglobincyanide method. *Clin Chim Acta*. ;6:538–544.
  36. Stocks J., Dormandy T.L. (1971). The autoxidation of human red cell. Lipid induced by hydrogen peroxide. *Br. J. Haematol*. 20: 95-111.
  37. Bennet, C.A. and Franklin, N.L. (1967). In: *Statistical Analysis in Chemistry and Chemical Industry*. John-Wiley and Sons Inc., New York, p. 133.

38. Paunio, M., Virtamo, J., Gref, C.G, Heinonen, O.P.( 1996). HDL cholesterol, Alcohol intake and coronary mortality in a male smokers. *British Medical Journal*;312:1200-3.
39. Esma,S.G.,Erdine,Z.,Serdar,H.(2003).Influence of acute exercise on oxidative stress in chronic smokers.*J. Sports Sci. Med*; 2: 98-105.
40. Steinberg DA (1997).Critical look at the evidence for the oxidation of LDL in atherogenesis.*Atherosclerosis*;13: 5-7.
41. Singh, R.B., Niaz, M.A., Sharma, J.P., Kumar, R., Bishnoi, I., Begom, R. (1994). Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. *Acta Cardiol*; 49: 441–52.
42. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Cann B.(2002).Factors associated with oxidative stress in human populations. *Am J Epidemiol* ; 156: 274-85.
43. Zhang, J. R., Cazars, A. R., Lutzke, B. S. and Hall, E. D. (1995). *Free Radicals Biol.Med.*; 18:1-10.

**For Correspondence:****Amir Khan**Email: [amiramu@gmail.com](mailto:amiramu@gmail.com)